PRISM offers a comprehensive genomic approach to transcription factor function prediction

Aaron M. Wenger,1 Shoa L. Clarke,2 Harendra Guturu,3 Jenny Chen,4 Bruce T. Schaar,5 Cory Y. McLean,1 and Gill Bejerano1,5,6

1Department of Computer Science, Stanford University, Stanford, California 94305, USA; 2Department of Genetics, Stanford University, Stanford, California 94305, USA; 3Department of Electrical Engineering, Stanford University, Stanford, California 94305, USA; 4Biomedical Informatics Program, Stanford University, Stanford, California 94305, USA; 5Department of Developmental Biology, Stanford University, Stanford, California 94305, USA

The human genome encodes 1500–2000 different transcription factors (TFs). ChIP-seq is revealing the global binding profiles of a fraction of TFs in a fraction of their biological contexts. These data show that the majority of TFs bind directly next to a large number of context-relevant target genes, that most binding is distal, and that binding is context specific. Because of the effort and cost involved, ChIP-seq is seldom used in search of novel TF function. Such exploration is instead done using expression perturbation and genetic screens. Here we propose a comprehensive computational framework for transcription factor function prediction. We curate 332 high-quality nonredundant TF binding motifs that represent all major DNA binding domains, and improve cross-species conserved binding site prediction to obtain 3.3 million conserved, mostly distal, binding site predictions. We combine these with 2.4 million facts about all human and mouse gene functions, in a novel statistical framework, in search of enrichments of particular motifs next to groups of target genes of particular functions. Rigorous parameter tuning and a harsh null are used to minimize false positives. Our novel PRISM (predicting regulatory information from single motifs) approach obtains 2543 TF function predictions in a large variety of contexts, at a false discovery rate of 16%. The predictions are highly enriched for validated TF roles, and 45 of 67 (67%) tested binding site regions in five different contexts act as enhancers in functionally matched cells.

[Supplemental material is available for this article.]

The complex spatiotemporal regulation of gene expression is a critical component in vertebrate development, evolution, and disease (Visel et al. 2009; Levine 2010). Understanding this regulation involves unraveling the cis-regulatory architecture, namely, the biological roles of transcription factors, their target genes in different biological contexts, and the regulatory elements such as promoters and enhancers through which they exert their effect (Michelson 2002).

The recent coupling of chromatin immunoprecipitation with deep sequencing (ChIP-seq) is allowing unprecedented and mostly unbiased access to the whole genome landscape of transcription factor (TF) binding (Bernstein et al. 2012). Hundreds of such experiments for different TFs under different conditions have revealed a few general phenomena. A typical TF reproducibly binds thousands of genomic regions in any given context. The majority of bound sites are distal, located 10–1000 kb upstream or downstream from the nearest transcription start site. Transcription factors almost invariably are found to bind near a large number (dozens to hundreds) of target genes involved in a shared biological function, with most of these binding sites also being distal (McLean et al. 2010). Interestingly, TFs also often bind not once but multiple times next to some of their best-known functional target genes. We have recently incorporated all of these observations into a new statistical test used to reveal the functions of a ChIP-seq data set, which we call GREAT (for genomic regions enrichment of annotations tool) (McLean et al. 2010).

GREAT and similar analyses reveal yet another key property of ChIP-seq experiments—their context dependence. While TFs are often pleiotropic, playing key roles in multiple independent cellular contexts, a ChIP-seq experiment reveals only the subset of functions relevant to the assayed cell population. For example, when SRF—an important regulator of muscle development—is assayed by ChIP-seq in immune cells, its role in muscle development is not readily apparent (Valouev et al. 2008). To examine the function of SRF in muscle cells, muscle cells must be assayed. Although ChIP-seq is a high-throughput approach, the required expense, time, and technical skill result in it being only rarely used as an exploratory tool to ask whether a TF has a role in a newly hypothesized cellular context. Almost invariably, a TF ChIP-seq is attempted in a given context only after the TF has already been shown to be important in said context. Yet, the human genome encodes 1500–2000 different transcription factors, and recent progress shows that many factors play important roles in biological contexts that remain to be discovered. Moreover, the genome itself encodes the transcriptional response of all cells in our body under numerous different cellular conditions.

Motivated by these observations, we aimed to apply transcription factor binding site prediction to produce novel hypotheses for transcription factor function in a wide range of contexts, as a guide for further experimental exploration. Recent technologies including protein binding microarrays (Berger et al. 2008), high-throughput SELEX (Jolma et al. 2010), and ChIP-seq itself have facilitated the quantification of the binding preferences of hundreds of different TFs. Meanwhile, decades of protein research have been collected into biological ontologies and large gene annotation.
repositories. And lastly, while single sequence/species prediction of transcription factor binding sites results in far too many erroneous predictions, the subset of binding site predictions that shows cross-species sequence conservation exhibits much higher specificity as measured by ChIP-seq occupancy of predicted sites (Xie et al. 2009) and a higher likelihood of residing within active enhancers (Cheng et al. 2008; Rada-Iglesias et al. 2012). Although a conservation-based assay misses many species-specific functional binding sites (Blow et al. 2010; Schmidt et al. 2010), it is not limited to a single cellular context and allows exploratory questions about the roles of a transcription factor.

Previous approaches to this challenge have focused on small numbers of TFs, gene promoters, and specific biological processes, thus ignoring the vast majority of binding events (Das et al. 2006; Down et al. 2007; Sinha et al. 2008). To extend this work, we here develop the PRISM (predicting regulatory information from single motifs) method, which combines genome-wide conserved binding site prediction with transcription factor and binding site function prediction. We introduce the excess conservation score, an improved measurement of binding site conservation that favors sites that are more conserved than neighboring nucleotides. We compile a nonredundant, high-quality library from more than 800 public transcription factor motifs, covering all major DNA binding domains, and predict 3.3 million binding sites for all factors across the human and mouse genomes. We then place GREAT (McLean et al. 2010), a tool for functional analysis of a set of cis-regulatory regions, in a novel statistical framework that lets us predict transcription factor and binding site functions en masse. In total, we infer more than 2500 transcription factor functions, covering nearly 7700 different target genes. We show that our inferences include hundreds of transcription factor function predictions directly supported by existing literature and annotations, for each of which we implicate tens to hundreds of novel binding sites. We validate a subset of our predictions experimentally in a variety of functional contexts. Lastly, we present novel hypothesized transcription factor functions with supporting evidence. We offer the PRISM predictions to the community through a web portal at PRISM.stanford.edu.

Results

Improving transcription factor binding site prediction using excess conservation

A long line of previous works (culminating in Xie et al. 2009) has defined a methodology for predicting conserved binding sites from a genome-wide multiple alignment and the position weight matrix, or motif, representation of transcription factor binding specificity. However, focusing on the motif alone ignores the surrounding sequence in which prediction is done. Mammalian genomes are full of long (100–1000 bp), highly conserved noncoding regions (Waterston et al. 2002; Bejerano et al. 2004). The more conserved a longer genomic stretch is, the more likely it is to include conserved binding site-like patterns in it by chance (see Fig. 1B). Accounting for this differential likelihood of false predictions has been valuable in improving earlier methods (Kheradpour et al. 2007).

We have developed an adjustment to the latest conservation metrics that accounts for the conservation level of the predicted binding site’s immediate genomic vicinity (Fig. 1A–C). We assign each binding site prediction an “excess conservation” score, which measures how unlikely it is for the binding site to be conserved by chance to the observed depth in a particular region of the genome based on the behavior of shuffled versions of its motif in similarly conserved regions of the genome (see Methods). Shuffled motifs have previously been shown to be the most realistic null model for motif-based prediction methods (Lewis et al. 2003; Kheradpour et al. 2007). The method explicitly favors binding sites that are conserved more strongly than surrounding sequence, which suggests evolutionary constraint aimed at transcription factor binding site preservation (Fig. 1C). While motif conservation-only metrics gravitate toward prediction in deeply conserved regions, the excess conservation adjustment produces predictions with a conservation profile matching closely to that of actual ChIP-seq binding sites (Fig. 1D). The excess conservation method also more accurately identifies binding sites, as measured by area under the curve analysis of overlap with ChIP-seq, for 44 of 47 (94%) examined transcription factors (Supplemental Table 1).

Genome-wide binding site prediction reveals trends in mammalian transcription regulation

We obtained 389 motifs covering 289 factors from UniPROBE (Newburger and Bulyk 2009), 133 motifs covering 90 factors from JASPAR (Bryne et al. 2008), and 294 motifs covering 151 factors from TransFac (Matys et al. 2006). Careful semiautomated curation to select only high-quality, nonredundant motifs (see Methods) resulted in 332 motifs, covering at least one member from every major DNA binding domain family (Fig. 2A).

For each motif, we identified the approximately 5000 instances genome-wide with the highest excess conservation scores, for a total of nearly 3.3 million predicted binding sites for the human and mouse genomes across all motifs at a false-positive rate of 0.6 (see Methods). While our predictions are encouragingly enriched in the proximal promoter (2.3-fold compared with genome-wide expectation), >90% of binding site predictions lie outside of proximal promoters (Fig. 2B).

The predictions reveal interesting trends in the propensity of certain DNA binding domain families to target genes more proximally or distally than others (Fig. 2C). We associate binding sites to target genes using default GREAT gene regulatory domains (basal domain: 5 kb upstream + 1 kb downstream; distal domain: up to 1 Mb in each direction to the nearest basal domain), which we previously have shown is ideal for analysis of distal binding sites from ChIP-seq (McLean et al. 2010). For the most proximal family, the E2F/TDF genes, >47% of binding site to target gene associations are within 5 kb of the transcription start site (TSS). Many fewer associations are within 5 kb for the most distal families: HMG (4.2%), Homeodomain (3.6%), and POU (3.2%). In fact, >93% of the predictions for the HMG, Homeodomain, and POU families are >100 kb from the TSS of the associated target gene.

Interestingly, the transcription factor families with the most distal predictions have the fewest downstream targets, showing a tendency to cluster around a relatively small number of target genes (Fig. 2D). In fact, a clear inverse relationship between distance to TSS and number of predicted target genes holds across the full set of motifs, with a Pearson correlation of −0.75 (Fig. 2E). No family has a markedly wider set of target genes than random expectation, but the C2H2 zinc-finger CTCF motif is a clear outlier (Fig. 2D,E), reflecting its special role in genome structure organization (Phillips and Corces 2009).

To examine which genes and gene families are most densely regulated, we calculated the fraction of base pairs in a gene’s regulatory domain that are covered by a binding site prediction. Not surprisingly, HOX genes are among the most densely regulated
When we grouped all target genes into families using Interpro domain composition and performed a Wilcoxon rank-sum test, numerous transcription factor families rose to the top, suggesting that the regulators themselves have the most upstream regulation (Fig. 2F; Supplemental Table 4).

Excess conservation binding site predictions overlapping GWAS SNPs
The NHGRI maintains a catalog of the most significant simple nucleotide polymorphisms (SNPs) associated with a growing number of diseases and traits, discovered using genome-wide association studies (GWAS) (Hindorff et al. 2009). Our excess conservation binding site predictions overlap 15 of these phenotype-associated SNPs (Supplemental Table 5), a significant overlap (1.86-fold enriched compared with dbSNP overlap, \(P\)-value < 0.018, Fisher's exact test) (see Methods). For at least five of these SNPs, the transcription factor that we predict to bind has itself been associated with the phenotype in question (Table 1). For example, rs445 is associated \(\left(\text{\(P\)} < 10^{-7}\right)\) with white blood cell count (Kamatani et al. 2010). The risk allele weakens a predicted binding site for c-MYB, a key player in the onset of leukemia, a cancer characterized by an abnormal increase in white blood cells (Jin et al. 2010). In other cases, such as rs339331, associated \(\left(\text{\(P\)} < 10^{-11}\right)\) with prostate cancer (Takata et al. 2010), the risk allele strengthens a potential binding site for HOXA13, a key factor in prostate gland development (Podlasek et al. 1999).
genes in the genome for any enriched function. GREAT (the genomic regions enrichment of annotations tool) never converts peaks to genes. Instead, each gene is assigned a putative “regulatory domain,” which always contains 5 kb upstream of and 1 kb downstream from its transcription start site and an extension up to the basal regulatory domain of the nearest upstream and downstream genes within 1 Mb. Given a list of genes for a particular term (e.g., actin cytoskeleton), GREAT computes the fraction of the genome covered by the regulatory domains of the genes in the list and the number of peaks hitting these regulatory domains. From this a binomial $P$-value is computed (see Fig. 1 in McLean et al. 2010).

We have previously shown that GREAT outperforms gene list–based or microarray-based tools at revealing biologically meaningful enrichments in ChIP-seq data sets (McLean et al. 2010). Our extensive comparisons featured four transcription factors—REST (NRSF), GABPA, SRF, and STAT3—in both human and mouse contexts, for which GREAT leverages distal binding sites to reveal accurate and specific function predictions (McLean et al. 2010). To compare our transcription factor and binding site predictions from motif and genome sequence alone to those obtained via antibody ChIP-seq in a particular cellular context, we predicted binding sites from high-quality motifs for the same four factors and analyzed the predictions with GREAT (Table 2).

**Figure 2.** Genome-wide excess conservation binding site predictions reveal fundamental properties of mammalian transcription regulation. (A) The curated library of 332 nonredundant high-quality transcription factor (TF) motifs includes members of all major DNA binding domain (DBD) families. (B) Distributions of all genomic bases (red) and all conserved binding site predictions (blue) as a function of distance from the transcription start site (TSS). While predictions are 2.3-fold enriched in the proximal promoter, >90% of them are distal. (C) Different DNA binding domain families exhibit different binding distance preferences relative to the TSS. (Black ticks) Median distances per motif; (green dot) the family median; random is the median of 332 uniform shuffles. (D) Number of predicted target genes for the different TF DBD families. Black ticks, green dots, and random are as in panel C. POUs and Homeo-domains cluster the most around target genes, while CTCF is at the opposite extreme. (E) Distance to TSS and number of target genes have a strong inverse correlation. (F) Transcription factors (blue) are the most densely regulated gene families in the human genome, as measured by the fraction of base pairs in the gene’s regulatory domain covered by a binding site prediction. Shown are all nonredundant significant terms after Bonferroni correction (see text).
PRISM identifies potentially causative binding sites affected by phenotype-associated genome-wide association single-nucleotide polymorphisms. For the shown cases, the risk allele either weakens (down arrow) or strengthens (up arrow) a binding site prediction for a transcription factor known to be relevant to the associated disease.

**Table 1. Biologically appealing PRISM predicted binding sites affected by GWAS risk alleles**

| SNP      | GWAS Phenotype         | PRISM Binding Site | Relevance of PRISM Factor to Phenotype | Risk Allele Effect on Binding Site | Nearest Genes |
|----------|------------------------|--------------------|----------------------------------------|-----------------------------------|---------------|
| rs445    | white blood cell count | c-Myc              | TF Motif: Non-risk: GACGTG<br>Risk: T | CDK6 (-55kb), PEX1 (-251kb)       |               |
| rs339331 | prostate cancer        | HOXA13             | TF Motif: TTTAGAG<br>Risk: T           | RFX6 (+12kb), VGLL2 (-377kb)      |               |
| rs909116 | breast cancer          | ERα                | TF Motif: TACC<br>Risk: T              | TNNT3 (+14kb), MRPL23 (-27kb)     |               |
| rs10508517 | diabetic blood pressure | SIX2               | TF Motif: AGATCA<br>Risk: A            | RSU1 (+138kb), CUBN (+174kb)      |               |
| rs12917703 | chronic kidney disease   | SREBF1             | TF Motif: GCAGTTGA<br>Risk: T          | UMOD (-4kb)                       |               |

GREAT analysis of REST and GABPA binding site predictions substantially agrees with analysis of ChIP-seq peaks for these factors, with ChIP-seq peaks overlapping 31%–71% of implicated binding site predictions when the enrichments agree (Table 2; Supplemental Tables 6, 7). GREAT analysis of SRF ChIP-seq data from human Jurkat cells generates enrichments that reflect the known role of SRF as the master regulator of actin (42 peaks, \( P < 10^{-18} \)) (Supplemental Table 8; McLean et al. 2010). Using our binding site predictions for SRF, we see this same result (\( P < 10^{-57} \)) from a broad set of 356 binding sites for 142 target genes (false discovery rate = 38%), the majority of which are not identified in this particular ChIP-seq set (Table 2). In addition, 155 of our binding site predictions for SRF are strongly associated with genes that cause a dilated heart phenotype when knocked out (\( P < 10^{-17} \); binding site FDR = 46%). SRF is well known for its role in heart development, and a conditional knockout of Srf itself in the developing mouse heart leads to a dilated heart phenotype (Parlakian et al. 2004). This experimentally supported result is not found when analyzing the SRF ChIP-seq data, which was generated using Jurkat cells, a T-cell-derived cell line unlikely to reflect the biology of the developing heart.

The enrichments for STAT3 differ markedly between the ChIP-seq and binding site prediction sets. The top enrichments for the STAT3 ChIP-seq data set reflect the context of the experiment, mouse embryonic stem cells (mESC) (see Supplemental Table 9). In contrast, GREAT analysis of genome-wide conserved binding site predictions for STAT3 highlights its well-known role in signaling (\( P < 10^{-15} \); 150 predicted binding sites; binding site FDR = 48%) and the immune system (\( P < 10^{-15} \); 145 sites; binding site FDR = 43%), two functions with no overlapping peaks in the mESC ChIP-seq data (Table 2). Conserved STAT3 binding sites and ChIP-seq data thus produce distinct yet complementary enrichments, which are equally supported by experimental literature.

GREAT analysis of our binding site predictions also produces novel, plausible hypotheses. For example, 98 predicted SRF binding sites show an association with target genes related to the regulation of insulin secretion (\( P < 10^{-23} \); binding site FDR = 28%) (Table 2). While, to our knowledge, this association has not yet been experimentally verified, a recent paper shows that insulin resistance in humans and mice is marked by increased SRF activity (Jin et al. 2011). Similarly, GREAT analysis implicates GABPA in regulating “general transcription by RNA polymerase I” (\( P < 10^{-11} \); 19 binding sites at FDR = 13%), an enzyme that transcribes ribosomal RNA. GABPA is known to regulate transcription of ribosomal proteins (Genuario and Perry 1996). Our predictions suggest that GABPA may function as a regulator of multiple facets of ribosome synthesis.

**The PRISM framework: Predicting biological roles, target genes, and enhancers for hundreds of transcription factors**

Motivated by the biological function predictions obtained for the four different factors, we set out to analyze the predicted binding sites from each of our 332 curated motifs using GREAT (McLean et al. 2010). We examined nine GREAT ontologies that provide more than 2.4 million facts about human and mouse gene roles in different biological processes, molecular functions, cellular components, phenotypes, molecular pathways, and gene families (Supplemental Table 10; see Methods).

Applying GREAT to binding site predictions from hundreds of transcription factors results in many TF function predictions (Table 3, stage 1). While GREAT accounts for multiple hypothesis test correction for multiple ontology terms against a single set of genomic regions, here we repeatedly apply GREAT to hundreds of sets, one for each motif. To control for multiple hypothesis testing in this framework, we used two filtering stages. First, we focused our attention on only up to the top 20 predictions per motif using a more stringent \( P \)-value, and removing broad terms that annotate many genes (see Methods). This resulted in keeping only 23% of the human, and 18% of the mouse GREAT predictions (Table 3, stage 2).

To properly account for multiple hypothesis testing, we then applied our entire method to the 2857 shuffled versions of transcription factor motifs used as null models in calculating the excess
Table 2. A comparison of GREAT transcription factor function predictions from PRISM binding site predictions versus ChIP-seq peaks for four different factors

| Transcription factor | Ontology | Top-ranked PRISM biological role | Experimental support in literature | PRISM predicted target genes and binding sites | ChIP-seq target genes and binding sites |
|----------------------|----------|----------------------------------|-----------------------------------|-----------------------------------------------|---------------------------------------|
| REST (NRSF)          | GO biological process | Neurontransmitter transport | “The putative REST target genes encode proteins that contribute to many different aspects of the neuronal phenotype: neurotransmitter receptors, ion channels, neurotransmitter-synthesizing enzymes, neuropeptides, cell adhesion molecules, synaptic vesicle proteins, and cytoskeletal components.” (Schoenherr et al. 1996) | 27 49 2.01 × 10⁻¹⁵ 3.95 | 30 55 Y |
| GO celluar component | GO molecular function | Abnormal synaptic transmission | Novel | 56 85 6.31 × 10⁻¹⁴ 2.17 | 61 93 — |
| GO molecular function | Mouse phenotypes | Cation channel activity | “The [putative REST target] genes encode proteins that contribute to many different aspects of the neuronal phenotype: neurotransmitter receptors, ion channels, neurotransmitter-synthesizing enzymes, neuropeptides, cell adhesion molecules, synaptic vesicle proteins, and cytoskeletal components.” (Schoenherr et al. 1996) | 71 98 1.24 × 10⁻¹³ 2.10 | 94 131 Y |
| PANTHER              | Pathway commons | Synaptic vesicle trafficking | 135 208 1.85 × 10⁻²⁵ 2.16 | 172 269 Y |
| Pathway commons      | Pathway commons | Transmission across chemical synapses | 23 34 2.99 × 10⁻⁸ 3.02 | 22 33 Y |

| GABPA                | GO biological process | Translation | “The CA-binding protein (GABP) [is] ... a strong positive regulator of several ribosomal protein (rp)-encoding genes.” (Genuario and Perry 1996) | 141 212 1.66 × 10⁻²⁰ 2.01 | 185 205 Y |
| GO cellular component | GO molecular function | Translation initiation factor activity | Novel | 34 50 3.15 × 10⁻⁷ 2.24 | 30 45 Y |
| GO molecular function | Mouse phenotypes | Increased single-positive T-cell number | Novel | 36 58 4.20 × 10⁻¹² 2.88 | 36 41 Y |
| PANTHER              | Pathway commons | General transcription by RNA polymerase | 67 143 5.23 × 10⁻¹⁷ 2.18 | 25 30 — |
| Pathway commons      | Pathway commons | Translation | 138 202 3.00 × 10⁻²¹ 2.08 | 196 223 Y |

| SRF                  | GO biological process | Muscle structure development | “SRF controls mutually exclusive programs of gene expression (growth vs. muscle differentiation).” (Miano et al. 2007) | 157 401 7.43 × 10⁻⁴³ 2.07 | 18 25 — |
| GO cellular component | GO molecular function | Actin cytoskeleton | “Genetic studies point to a crucial role for SRF in ... normal actin cytoskeleton biology.” (Miano et al. 2007) | 142 356 4.84 × 10⁻⁵⁸ 2.63 | 37 42 Y |
| GO molecular function | Mouse phenotypes | Structural constituent of muscle | “SRF [has a role] in controlling muscle contractile gene expression.” (Miano et al. 2007) | 26 66 3.97 × 10⁻¹⁶ 3.29 | 4 6 — |
| PANTHER              | Pathway commons | Dilated heart ventricles | “Heart-specific deletion of SRF in the embryo results in ... dilated cardiac chambers.” (Parlakian et al. 2004) | 59 155 2.13 × 10⁻¹⁸ 2.19 | 4 4 — |
| Pathway commons      | Pathway commons | Cytoskeletal regulation by Rho GTPase | “The Rho family GTPases ... activate transcription via SRF.” (Hill et al. 1995) | 37 90 4.59 × 10⁻²³ 3.48 | 10 17 — |
|                      |                      | Regulation of insulin secretion by acetylcholine | Novel | 28 98 2.90 × 10⁻²⁶ 3.63 | 3 3 — |

(continued)
| Transcription factor | Ontology               | Top-ranked PRISM biological role | Experimental support in literature                                                                 | Selected citation          | PRISM predicted target genes | PRISM binding sites | ChIP-seq target genes | ChIP-seq binding sites | ChIP-seq GREAT significant |
|----------------------|------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------|------------------------|-----------------------|------------------------|--------------------------|
| STAT3                | GO biological process  | Negative regulation of signal transduction | “SSI-1, … a target of Stat3, … is responsible for negative feedback regulation of the JAK–STAT pathway.” (Naka et al. 1997) | 54 150 5.13 × 10^{-16} 2.08 26 51 — |                         |                         |                       |                        |                          |
|                      | GO molecular function  | Transforming growth factor β binding | Novel                                                                                               |                             |                         |                         |                       |                        |                          |
|                      | Mouse phenotypes      | Abnormal spleen B-cell follicle morphology | “STAT3-deficient mouse B cells … do not differentiate into IgG-secreting [plasma cells].” (Schmidlin et al. 2009) | 8 26 5.96 × 10^{-7} 3.15 3 6 — |                         |                         |                       |                        |                          |
|                      | Pathway commons       | Signaling events mediated by TCPTP  | “TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation.” (Yamamoto et al. 2002) | 52 145 1.52 × 10^{-19} 2.33 18 28 — |                         |                         |                       |                        |                          |
|                      |                       |                                  |                                                                                                     |                             | 48 119 1.79 × 10^{-18} 2.50 16 31 — |                         |                       |                        |                          |

(Columns 2–8) The top PRISM function prediction per ontology for the four factors highlighted in McLean et al. (2010), along with supportive quotes from the literature and PRISM enrichment statistics.

(Columns 9–11) A comparison to observed peaks and GREAT enrichments from ChIP-seq in human Jurkat cells or mouse embryonic stem cells. PRISM independently discovers literature-supported functional enrichments observed in ChIP-seq (for REST and GABPA). By accessing conserved binding site predictions directly from the genome, PRISM discovers literature-supported functions that are not observed in context-specific ChIP-seq experiments (for SRF and STAT3).
conservation score (Fig. 3A) (see Methods). We expect such shuffled motifs, by and large, to lack real functional signals, although the method is conservative because some shuffles may capture whole or partial binding preferences of uncharacterized factors and complexes.

For each biological role (annotation term), we used the total fraction of shuffled motifs for which the term satisfies the GREAT significance thresholds to estimate the expected number of times the term would be falsely called as significant for a set of 332 motifs. Any term expected to occur falsely once or more was excluded (see Methods). Following this very stringent pruning, only 22% of human and 9% of mouse TF function predictions were retained (Table 3, stage 3).

Our shuffled motif TF function predictions can also be used to compute the false discovery rate (FDR) of the original and filtered set, by harshly assuming that all shuffled enrichments are false (see Methods). We see that while the TF function FDR of the human original GREAT predictions is 50.5%, the filtered predictions have a much more appealing FDR of 16.4%. Similarly, for mouse the FDR improves from 59.3% to 17.8%, a more than threefold improvement for both species (Table 3).

In summary, we predicted binding sites using the excess conservation score (Fig. 3A, Naya et al. 2002). The approach implicates MYF5 in regulating the myosin complex (Pownall et al. 2002). PRISM predicts muscle-related roles for all five (Supplemental Table 13). Furthermore, the actual function prediction differs between the factors, reflecting their different biological roles in muscle formation. PRISM correctly implicates MYF5 in regulating the myosin complex (P < 10^{-5}; 59 sites, binding site FDR = 45%; mouse), MEF2A in broader regulation of contractile fiber (P < 10^{-12}; 128 sites, binding site FDR = 47%; human), and MYOD1 in broad regulation of striated muscle tissue development (P < 10^{-22}; 236 sites, binding site FDR = 50%; mouse). These different functional roles have all been validated experimentally (Supplemental Table 13). PRISM also offers different perturbation predictions. For example, it predicts that both MYOG (P < 10^{-24}; 146 sites, binding site FDR = 37%) and MYF6 (P < 10^{-10}; 110 sites, binding site FDR = 50%) disruption results in general abnormal muscle development. Both predictions have been validated in mouse (Supplemental Table 13). Furthermore, in humans, MYF6 mutations have been associated with Becker muscular dystrophy (Kerst et al. 2000). For MEF2A, PRISM predicts that disruption results specifically in abnormal cardiac output (P < 10^{-5}; 47 sites, binding site FDR = 47%). Indeed, MeF2a knockout mice suffer from severe heart phenotypes resulting in sudden death associated with heart failure and cardiac arrest (Naya et al. 2002).

| Table 3. PRISM’s filtering of GREAT’s raw transcription factor function predictions |
|---------------------------------|---------------------|---------------------|---------------------|---------------------|
|                                | Stage 1: GREAT on binding site predictions | Stage 2: Top significant GREAT terms | Stage 3: PRISM terms (via blacklisting) | PRISM vs. GREAT on binding site predictions |
|                                | Obtained = GREAT | Dropped | Kept | Kept = PRISM | GREAT predictions kept | FDR improvement | Fraction loops improvement |
| hg18                           | Num. of TF-term associations | 31,946 | 24,417 | 7529 | 5871 | 1658 | 5.2% | 308% | 329% |
|                               | TF-term FDR | 50.5% | 50.8% | 49.5% | 58.8% | 16.4% | 3.7% | 10.9% | 4.8% |
|                               | Closed loop % | 3.3% | 2.7% | 5.3% | 3.7% | 10.9% |
| mm9                            | Num. of TF-term associations | 67,755 | 55,241 | 12,514 | 11,341 | 1173 | GREAT predictions kept | 1.7% | 333% | 455% |
|                               | TF-term FDR | 59.3% | 55.9% | 74.4% | 80.3% | 17.8% | 4.0% | 12.4% | 0.2% |
|                               | Closed loop % | 2.7% | 2.2% | 4.8% | 4.0% | 12.4% |

In stage 1, statistics are provided for running GREAT on all motifs, without any correction. These predictions are filtered once in stage 2 for top enrichments per TF, term specificity, and increased statistical stringency. In stage 3, multiple hypothesis testing correction is applied, using GREAT enrichments for motifs shuffles, to generate a blacklist of ontology terms to exclude (see Fig. 3A; Methods). For human (hg18) and mouse (mm9), the first row shows the number of predictions obtained, dropped, and retained at the different stages. The second row provides an estimate of the false discovery rate for each of the intermediate sets. The third row provides the fraction of function predictions that can be computationally validated from the ontology terms associated with the regulating factor (called “closed loops”).

PRISM offers both breadth and depth of biological role predictions

PRISM predictions offer not only breadth (as reflected in Supplemental Fig. 10B), but can also offer depth and accuracy in terms of specific function and perturbation predictions. For example, five genes have been previously identified as key master regulators of muscle differentiation: MYOD1, MYOG, MYF5, MYF6 (MRF4), and the MEF2 family (Pownall et al. 2002). PRISM predicts muscle-related roles for all five (Supplemental Table 13). However, the actual function prediction differs between the factors, reflecting their different biological roles in muscle formation. PRISM correctly implicates MYF5 in regulating the myosin complex (P < 10^{-5}; 59 sites, binding site FDR = 45%; human), MEF2A in broader regulation of contractile fiber (P < 10^{-12}; 128 sites, binding site FDR = 47%; human), and MYOD1 in broad regulation of striated muscle tissue development (P < 10^{-22}; 236 sites, binding site FDR = 50%; mouse). These different functional roles have all been validated experimentally (Supplemental Table 13). PRISM also offers different perturbation predictions. For example, it predicts that both MYOG (P < 10^{-24}; 146 sites, binding site FDR = 37%) and MYF6 (P < 10^{-10}; 110 sites, binding site FDR = 50%) disruption results in general abnormal muscle development. Both predictions have been validated in mouse (Supplemental Table 13). Furthermore, in humans, MYF6 mutations have been associated with Becker muscular dystrophy (Kerst et al. 2000). For MEF2A, PRISM predicts that disruption results specifically in abnormal cardiac output (P < 10^{-5}; 47 sites, binding site FDR = 47%). Indeed, MeF2a knockout mice suffer from severe heart phenotypes resulting in sudden death associated with heart failure and cardiac arrest (Naya et al. 2002).
Objective experimental support for PRISM biological role predictions

The same ontologies used by PRISM to infer biological roles of a transcription factor from its predicted binding sites can sometimes be used to directly confirm a role prediction in an objective, unbiased manner (and thus further support our mostly novel binding site predictions). Because PRISM makes its predictions based solely on the annotations of the predicted target genes, the ontologies themselves can provide such support when the transcription factor itself is tagged with the same function that PRISM identifies as enriched among its downstream target genes. For example, the PRISM prediction that GLI2 is involved in “skeletal system development” (because a surprisingly high number of its predicted target genes are labeled as such) is confirmed by the Gene Ontology, which tags GLI2 itself with the same term and provides a supporting reference (Mo et al. 1997).

This objective test was used to optimize PRISM’s design. We have performed an extensive search in parameter space, varying multiple values and design choices (see Methods). The approach we describe here obtains an optimum between computational validation rate and prediction breadth. Indeed, in the unfiltered set of human GREAT predictions, only 3.3% of predictions can be confirmed computationally, a validation rate that improves 3.3-fold in the PRISM subset. Similarly, for the unfiltered mouse GREAT predictions, only 2.7% can be validated computationally, improving 4.5-fold in the PRISM subset (Table 3). In total, 180 (11%) of the 1658 human-based predictions of biological roles for transcription factors and 145 (12%) of the 1173 mouse-based predictions are confirmed this way (Supplemental Tables 11, 12). The number of observed confirmations is highly significant ($P < 2 \times 10^{-10}$), because no more than 16 matches (1%) were observed in 50,000 simulations that apply a transcription factor’s annotations to its shuffled motifs (Fig. 3D).

Distal binding sites contribute greatly to the PRISM approach. With only proximal binding sites (~5 kb to +1 kb from TSS), PRISM in human only predicts 50 (3.6-fold less) biological roles that are confirmed by the ontologies (Fig. 3D), and only 23 (6.3-fold less) mouse predictions confirmed by the ontologies.

While direct ontology support can confirm function predictions, the lack of such support does not imply an incorrect prediction. For example, as discussed above, PRISM predicts that SRF regulates genes that compose the “actin cytoskeleton.” Although SRF is known as the master regulator of the actin cytoskeleton (Miano et al. 2007), it acts in the nucleus and is not involved in building the cytoskeleton itself; thus, it is appropriately not annotated with the Gene Ontology Cellular Component term “actin cytoskeleton.” Other missing confirmations are due to the incompleteness of annotation. For example, PRISM predicts 91 GATA6 binding sites near 23 genes whose mutations lead to abnormal pancreas development ($P < 10^{-12}$; binding site FDR = 43%). While GATA6 currently lacks the same annotation, a very recent study

---

Figure 3. PRISM transcription factor and binding site function predictions. (A) PRISM combines excess conservation binding site prediction (Fig. 1) with GREAT function prediction from proximal and distal sites into a novel statistical framework to arrive at thousands of transcription factor (TF) function predictions, at a false discovery rate of 16%. Numbers are summed over human and mouse (see text). (B) Distribution of PRISM human TF function prediction across the major DNA binding families. (C) Most of the binding sites that support PRISM predictions—including high confidence confirmed predictions—are distal from putative target genes. (D) PRISM predictions are highly enriched for support by previous literature. The GREAT ontologies tag the transcription factor itself with the function predicted by PRISM as enriched among its target genes 180 (11%) times, Z-score = 77, $P < 1/50,000$ simulation runs (red); 3.6-fold enriched over using only proximal binding sites.
identified inactivating mutations in GATA6 as the most common cause of pancreatic agenesis in humans (Allen et al. 2011). Similarly, other unconfirmed PRISM predictions may well represent accurate novel predictions.

Overlap of PRISM annotated binding site predictions with ChIP-seq

To evaluate the accuracy and comprehensiveness of individual PRISM binding site predictions, we examined the overlap of binding site predictions with ChIP-seq peaks for four transcription factors with literature-confirmed PRISM biological function predictions. For all four factors, a single ChIP-seq experiment in a single context confirms a considerable fraction of the predicted sites: from 7% for CRX (mouse) to 56% for REST (human). Importantly, this represents a lower bound on the accuracy of binding site prediction, because other ChIP-seq experiments in the same or different contexts likely will support even more binding sites (Fig. 4A).

From all the binding site predictions, PRISM annotates a subset with specific biological roles. The overlap with ChIP-seq for the annotated subset is significantly larger than for the full set of predictions: >25% for CRX and SRF (mouse), and >60% for REST and GABPA (human). Again, this provides a lower bound on accuracy. It demonstrates that the accuracy of the PRISM-annotated subset of the binding site predictions is often much better than estimated for the full set of predictions (Fig. 4A).

To evaluate the comprehensiveness of PRISM, we examined which fraction of the ChIP-seq peaks for a transcription factor is identified by a PRISM binding site prediction. Interestingly, a number of ChIP-seq peaks for each of the four examined factors lack a match to the transcription factor motif in the genome of the assayed species, ranging from 66% of SRF ChIP-seq peaks to 19% of GABPA peaks. Of the peaks with a motif match in the assayed species, PRISM hits between 5.3% (for SRF) and 69% (for REST) of GABPA peaks. Of the peaks with a motif match in the assayed species, PRISM hits between 5.3% (for SRF) and 69% (for REST) of the experimentally identified peaks. The comprehensiveness significantly improves when examining only those ChIP-seq peaks in the regulatory domains of genes with a relevant biological function. For instance, 16.8% of the SRF peaks near actin cytoskeleton genes are identified by PRISM, compared with 5.3% of all peaks (3.2-fold increase). For REST, PRISM identifies >83% of the ChIP-seq peaks near neurotransmitter transport genes. Thus, while PRISM does not identify every ChIP-seq binding site, it does discover a sizeable fraction, particularly when considering the most confident ChIP-seq peaks that are connected to a specific biological role (Fig. 4B).

Enhancer assays support a role for MYF6 in pancreas as predicted by PRISM

In addition to its known role in muscle development, PRISM predicts a role for myogenic factor 6 (MYF6) in pancreas development (P-value = 1.67 $\times$ 10$^{-10}$; 85 binding sites; binding site FDR = 46%). MYF6 is indeed expressed in the pancreas (Kutlu et al. 2009), but to our knowledge no role in pancreas development has yet been characterized. To examine whether the predicted MYF6 target enhancers drive activity and are responsive to MYF6 in pancreas cells, 15 elements were tested in luciferase enhancer assays in the mPAC cell line, which is derived from pancreatic ductal cells.

Six of the 15 tested elements function as enhancers (luciferase activity >2 x empty vector) in the pancreatic cell line (Fig. 5A). All six of the positive elements respond significantly when MYF6 is ectopically expressed via cDNA cotransfection. Two other elements (elt4, which putatively regulates HES1, and elt13, which putatively regulates INSM1) are not enhancers in the standard mPAC cell line but do drive activity in response to ectopically expressed MYF6 (Fig. 5A).

Enhancer assays support the accuracy of PRISM predictions

Four other transcription factor to function predictions were tested using luciferase enhancer assays. Specifically, we examined 20 putative targets of RUNX1 in lung inflammation (P-value = 2.71 $\times$ 10$^{-15}$; 153 binding sites; binding site FDR = 50%) using NHBE cells.

Figure 4. Overlap of PRISM binding site predictions with ChIP-seq. PRISM binding site predictions for CRX (m = mouse), GABPA (h = human), REST (human), and SRF (mouse) were overlapped with ChIP-seq binding sites for the same four factors. Overlap was observed both for the full set of binding site predictions and a subset annotated by PRISM in a particular functional role (“sensory perception of light stimulus” for CRX, “translation” for GABPA, “neurotransmitter transport” for REST, and “actin cytoskeleton” for SRF). (A) Percent of PRISM binding site predictions hit by a ChIP-seq peak. (B) Percent of ChIP-seq peaks hit by a PRISM binding site prediction. Only ChIP-seq peaks with a match to the transcription factor motif in the reference species were considered (CRX: 74%; GABPA: 81%; REST: 60%; SRF: 34%).
14 targets of STAT1 in regulation of angiogenesis \( (P\text{-value} = 1.22 \times 10^{-10}) \), 96 binding sites; binding site FDR = 49%) using HUVEC cells, eight targets of MYF6 in abnormal muscle development \( (P\text{-value} = 3.27 \times 10^{-11}) \), 110 binding sites; binding site FDR = 50%) using UaSMC cells, and 10 targets of MEF2A in myofibril \( (P\text{-value} = 1.31 \times 10^{-12}) \), 122 binding sites; binding site FDR = 49%) using UaSMC cells. The majority of the enhancers predicted by PRISM to drive activity are responsive to the predicted transcription factor in the appropriate context. Across all examined elements, 67% successfully drive activity and are responsive to the predicted transcription factor (Fig. 5B).

**Discussion**

As we (Table 2) and others have shown, TF binding is cell type and condition dependent. Here we develop PRISM, a novel approach to predict broad TF functions directly from the genome. It is important to stress that PRISM does not attempt to predict TF occupancy in any particular context (i.e., to offer an alternative to ChIP-seq). It is clear that our understanding of the rules that govern gene regulation is not sufficient (e.g., Fig. 4). Rather, we show that cross-species conserved binding site prediction has become powerful enough to allow us to obtain a subset of binding sites for the predicted factor that is accurate enough and large enough to allow us to correctly predict transcription factor functions.

The general approach has been applied successfully in the past (Das et al. 2006; Down et al. 2007; Sinha et al. 2008). Our main contributions here are:

1. Unprecedented scope—we use more than 300 different motifs and test them against a vast body of gene function annotation, far more vast than has ever been done before. Hundreds of additional motifs will soon become available, and the body of gene function annotation is constantly on the rise.

2. Distal binding sites are accounted for—distal binding sites make the majority of observed and predicted binding events (Fig. 2; McLean et al. 2010). They contribute markedly toward our ability to make accurate TF function predictions (Fig. 3D). Using the GREAT test, we let them pull their full weight, whereas other screens before have discarded all but proximal promoter events alone.

3. We develop a rigorous, nontrivial, and purposefully conservative framework to ensure the quality of our TF function prediction. We improve conserved binding site prediction, we use a harsh null model of shuffled versions of our motifs, and we exclude function predictions that arise from our null.

The results we obtain are in line with our expectations: Our conserved binding site predictions have a relatively high FDR (60%). The FDR, however, markedly improves to 40% when one considers only the subset over which we make TF function predictions, supported by our experimental results (Fig. 5). Most importantly for the goal at hand, our TF function prediction FDR of 16% is appealingly low.

Our rigorous pruning leaves in PRISM only 5.2% of the human transcription factor function predictions that GREAT makes from conserved binding site predictions. This harsh pruning, however, markedly improves by a factor of more than 3 both our...
FDR and the fraction of predictions we can validate computationally from the annotations of the regulating TF (Table 3). To learn more about the nature of the ontology terms that PRISM blacklists, we used a set of conserved nonexonic genomic elements (CNEs). If we pick 10,000 random subsets of CNEs and create a blacklist from them the same way done in PRISM from motif shuffles, we obtain 2279 terms to blacklist (with $E$-value > 1). One thousand seven hundred thirty-three (76%) of these make up a full 70% of PRISM’s shuffled motifs–based blacklist. This suggests that the majority of PRISM’s blacklist derives from the nonrandom distribution of CNEs, well known to be rich in binding sites and their predictions.

Vertebrate transcription regulation is proving to be a complex affair (Bernstein et al. 2012). Large empty gene deserts are now appreciated to be packed with conserved noncoding and active cis-regulatory sequence. Transcription factors thought to form narrow cascades, directly binding a handful of targets, are found to bind thousands of loci in a single context, some conserved, others not, many with no obvious effect on their target genes in perturbation experiments. Adding to this emerging picture, our own analysis suggests that the transcription factors themselves are among the most densely regulated gene families in the mammalian genome. Here we provide windows to this complex system by designing a comprehensive framework for binding site and transcription factor function prediction for a wide range of human and mouse transcription factors and offering them to the community for further exploration. With the recent advent of high-throughput genome editing technologies, PRISM makes a particularly timely contribution (Joung and Sander 2012; Pennisi 2012).

Methods

Multiple genome alignments and phylogenetic tree

All comparative genomic analyses with a human reference used the human-anchored MULTIZ alignment of 44 vertebrates available from UCSC for the hg18 assembly along with the corresponding phylogenetic tree and branch lengths (Kent et al. 2002). Mouse analyses used an extension of the mm9-based MULTIZ alignment of 30 vertebrates from UCSC that includes the same 44 species as the human alignment. Only the eutherian mammals were considered for binding site prediction, and exon and repeat regions were ignored using UCSC annotations. Similar UCSC hg18-based MULTIZ alignments of 17 and 28 vertebrates were used for comparison to evaluate trends in multiple alignments as new species are added.

Transcription factor motif library curation

To obtain a nonredundant set of high-quality motifs, we combined publicly available motifs from UniPROBE (Newburger and Bulyk 2009), JASPAR (Bryne et al. 2008), and TransFac public version 7.0 (Matys et al. 2006). We associated each motif with the gene or genes it describes. Because of high redundancy between and within the different resources and low sample sizes for older entries, we clustered all motifs for a given gene, and used semiautomated curation to identify the highest-quality motif(s) for each factor. Among highly similar motifs for the same gene, we favored motifs derived from larger sample sizes, and higher information content respecting general expectations from related family members. This reduced our library from 816 to a high-quality nonredundant subset of 332 motifs, sampling all major DNA binding domains (Fig. 2A; Supplemental Fig. 5).

Single genome transcription factor binding site prediction

We predicted binding sites in a single genome or region using position weight matrix models of transcription factor binding specificity. Position frequency matrices ($f_{ij}$) were converted to position weight matrices (PWMs) ($p_{ij}$) by weighting each column by its information content (Kel et al. 2003).

Information content of column $i$: $IC(i) = 2 + \sum_{k=A,C,G,T} f_{ki} \log_2 f_{ki}$

Weight of base $j$ in position $i$: $p_{ij} = IC(i) \cdot f_{ij}$

Position weight matrix (motif) sequence scores were normalized by dividing by the maximum attainable score. Sequences with a score of at least 0.8 (i.e., matching at least 80% of the possible information content) were considered matches to the motif.

Motif shuffling

For each transcription factor motif, we generated up to 10 null model motifs by shuffling its columns. In shuffling, we preserved adjacent CpG columns, ensured that the shuffles did not resemble any known transcription factor motif or each other, and maintained the “information content profile” (by only swapping high/low information columns with other columns in the same class defining 0.7 bits as the minimum information of a “high” column) (Supplemental Fig. 6).

We defined the similarity of two motifs in a functional manner as the fraction of binding site predictions that overlap. We predicted binding sites with the two factors (see above) over a subset of human genomic gene deserts likely depleted for functional binding events (Ovcharenko et al. 2005). For each offset, $i$, at which the two motifs overlap, we counted the number of overlapping predictions, picked the highest, and normalized:

$$\text{Similarity} (\text{motif } A, \text{motif } B) = \max (\frac{\# \text{ times motif } A \text{ and motif } B \text{ overlap at offset } i}{\# \text{ of predictions for motif } A \times \# \text{ of predictions for motif } B}).$$

In generating shuffled motifs, a similarity threshold of 0.2 was used to reject motifs that resemble known transcription factor motifs or other shuffles of the same motif. This process resulted in 2857 shuffles for the 332 motifs (Supplemental Fig. 7).

Robust binding site prediction across a multiple alignment

The inclusion of more species in a comparative analysis improves detection of conserved regions (Margulies et al. 2006), but it also fragments multiple alignments into smaller blocks (Supplemental Fig. 1). The fragmentation separates nearby genomic bases in alignment space, falsely splitting or distancing binding sites across alignment blocks (Supplemental Fig. 2). To quantitify the effect of alignment fragmentation on prediction sensitivity, we considered the subset of binding site predictions confirmed by overlap with an ENCODE ChIP-seq peak from Supplemental Table 2 (see below). In a 17-way multiple alignment, 11% of confirmed binding site predictions would be lost due to alignment fragmentation without corrective measures, with the loss rate increasing to 16.7% in a 44-way alignment, and projected to grow linearly to nearly 30% of confirmed predictions in a forthcoming alignment of 100 species (Supplemental Fig. 3).

To overcome this artifact and recover all lost predictions, we padded alignment blocks with 30 bp (longer than the longest analyzed motif) of adjacent sequence from the genomes of all aligned species, collapsed binding site predictions to their single
start coordinate, and placed them on their respective genome (Supplemental Fig. 2A). To robustly predict conserved binding sites, the distance between motif matches was defined as the maximum of the distance measured in the reference and non-reference species genomic coordinates, with the multiple alignment used only to map start positions back to the genome (Supplemental Fig. 2B). We associated motif matches at a distance of up to 20 bp upstream or downstream, previously shown to be optimal for providing robustness to biological or artificial binding site shifting (Kheradpour et al. 2007).

After associating binding sites in reference and all aligning species, we calculated for every binding site: (1) the number of species with a matching binding site prediction; (2) the total branch length (BL) of the tree over which the binding site is conserved (Kheradpour et al. 2007); and (3) the weighted Bayesian branch length (BBL), which weights phylogenetic distance between species with the binding site match probability (or quality) in each species. BBL was previously shown to outperform BL for motif conservation score and is extensively discussed in Xie et al. (2009).

Efficient conserved binding site prediction
To predict binding sites, we slide a cursor column-by-column in the multiple alignment, scoring every reference position with all motifs and retaining all reference binding site predictions in a window. Given the objective to predict binding sites in the reference genome, one may avoid scoring sequences in an aligning species if the reference does not contain a corresponding binding site nearby, within the allowed local misalignment window (Supplemental Fig. 4A).

Implementing this optimization eliminated the need to predict at 90.4% of aligning positions (Supplemental Fig. 4B), reducing the prediction computation time of the human set from 822 h to 131 h (6.3-fold speed-up) on a cluster of Dell PowerEdge 1950 computers with 2.66 GHz Intel Xeon processors and 16 GB RAM (Supplemental Fig. 4C).

Excess conservation score
The excess conservation framework (Fig. 1A) rescores every motif binding site prediction according to a null distribution of scores of shuffled versions of the motif in genomic windows of 100 bp of similar conservation level. Formally:

\[
\text{Excess conservation score} = -\log_{10}(\text{Probability over})
\]

and so forth for shuffled motif scores in 100bp genomic windows of similar conservation) that

\[
\text{(shuffled motif score} \geq \text{observed real motif score})
\]

To compute it, we partition the reference genome into genomic windows of similar conservation: First, every base in the reference genome is given a weighted “% identity” score from 0% (found only in the reference species) to 100% (same base across the eutherian phylogeny) by calculating the total branch length over which the reference base pair is matched in the multiple alignment as a fraction of the complete branch length in the phylogeny. We then smooth the single position values by averaging over a 100-bp window centered on it, and group into 1% bins.

Next, for every motif m, we generate a set of shuffles \(M_m\) (as above). We predict over the reference genome using all shuffled motifs and bin the scores for shuffled motifs into frequency histograms according to the genomic conservation bins just described (Supplemental Fig. 8). We then go back, conceptually, through the reference genome and predict using the motif itself. Every prediction has a certain motif score and is done in a genomic 100-bp neighborhood of certain conservation. We use the frequency curves for that particular genomic neighborhood value to derive the empirical \(P\)-value of observing the motif score in that conservation neighborhood. The excess conservation score is \(-\log_{10}\) of this \(P\)-value (see formula above).

Note that the excess conservation framework can be applied to any motif scoring method. Here it is applied to the Bayesian branch length (BBL) score (above). As anticipated, when the same motif is equally conserved in two different genomic locations, its excess conservation score is higher in less conserved genomic windows (Fig. 1B,C; Supplemental Fig. 8A). In addition, when two different motifs are equally conserved in equally conserved genomic windows, the motif with higher information content has a higher excess conservation score, reflecting the higher specificity of its shuffles (Supplemental Fig. 8B).

Binding site predictions in the reference genome were retained and ranked by excess conservation score, if they were supported by at least four additional species, with a branch length (BL) score of at least two substitutions per site and an excess conservation score of at least 1.3 (i.e., the \(P\)-value of the observed motif score in similarly conserved windows \(\leq 0.05\)).

Evaluating accuracy of binding site prediction using ChIP-seq data
We used the UCSC Table Browser to download transcription factors ChIP-seq peaks (binding sites) assayed in human cells by the ENCODE Consortium (Bernstein et al. 2012). When multiple ChIP-seq experiments or replicates were available for the same factor, we selected the one with the largest number of peaks, yielding 56 distinct transcription factor sets. All 47 transcription factors for which we had a motif in our library were used (Supplemental Table 2).

The accuracy of binding site prediction before and after the excess conservation adjustment is summarized by area under the curve of precision-recall curves (Supplemental Table 1). We considered a binding site to overlap a ChIP-seq peak if at least one base pair overlapped. The conservation neighborhood for ChIP-seq peaks in Figure 1D is measured at the peak center.

To evaluate the overlap for functionally annotated binding sites (Fig. 4), four ChIP-seq sets from appropriate functional contexts were identified: CRX in mouse retina (Corbo et al. 2010), GABPA in human epithelial cells (Bernstein et al. 2012), REST in human Jurkat cells (Valouev et al. 2008), and SRF in mouse cardiomyocytes (He et al. 2011). To evaluate sensitivity (fraction of ChIP-seq peaks hit by a binding site prediction), only the ChIP-seq peaks with a match to the motif in the reference species (PWM threshold = 0.8) were considered.

Identifying binding site overlap with GWAS SNPs
The NHGRI GWAS catalog of disease-associated SNPs (Hindorff et al. 2009) was obtained from the UCSC Genome Browser “gwasCatalog” track (hg18 assembly). All PRISM binding site predictions that overlap the SNP by at least one base pair were identified (Table 1; Supplemental Table 5). The association of ESR1 (ER-alpha) (ER-α) with rs909116 is through a predicted binding site for the paralogous factor ESRRB (ERR-alpha) (ERR-α) (protein similarity BLASTP E-value \(\leq 10^{-45}\)). Statistical enrichment of overlap of binding site predictions with GWAS SNPs was calculated using a one-tailed Fisher’s exact test: dbSNP build 130 has 14,985,544 single nucleotide SNPs; the NHGRI GWAS catalog associates 3776 of these SNPs with a phenotype; PRISM binding
site predictions overlap 32,069 SNPs of which 15 are connected to a phenotype.

PRISM en masse transcription factor function prediction

PRISM function predictions were obtained in three stages (Fig. 3A): In stage 1 (Table 3) for each of our 332 transcription factor motifs, the top 5000 excess conservation binding site predictions in human and mouse were analyzed using GREAT v1.7 (McLean et al. 2010). Binding sites were associated with target genes using the GREAT default “Basal plus extension” association rule with default distances of 5 kb upstream, 1 kb downstream, and up to 1 Mb extension, or up to the next gene. We used the default GREAT filters for significant terms: region-based fold enrichment ≥2, and a region-based and gene-based false discovery rate (FDR) Q-value ≤0.05, with the additional requirement that at least five genes with the term were hit. Analysis was done over nine GREAT ontologies—the three Gene Ontology domains (Ashburner et al. 2000), Mouse Phenotypes (Blake et al. 2009), PANTHER Pathway (Mi et al. 2007), Pathway Commons (Cerami et al. 2006), BioCyc Pathway (Caspi et al. 2008), TreeFam (Ruan et al. 2008), and HGN Gene Families (Supplemental Table 10; Bruford et al. 2008).

In stage 2 (Table 3), we pruned our results to focus attention on the top enrichments. We limited to the top 20 terms per ontology for each motif, ignored broad terms annotated to more than 500 genes, and required an uncorrected region-based GREAT P-value ≤ 10⁻⁵.

In stage 3 (Table 3), to provide multiple testing correction for running GREAT 332 times per genome, we used our shuffled motifs. We separately repeated the entire GREAT analysis with all 2857 runs of shuffled motifs: (i) P_{real} = P_{shuffle}, (ii) P_{shuffle} = P_{real}, (iii) P_{real} = P_{shuffle}, (iv) FDR = P_{real}/P_{real} = P_{shuffle}/P_{real}

![Image or Diagram](image-url)

To evaluate PRISM with only proximal binding sites (Fig. 3D), we analyzed the set of top binding site predictions for each motif with GREAT v1.7 using only basal regulatory domains (5 kb upstream of and 1 kb downstream from the TSS). Shuffled motifs were used to calculate proximal-specific Expected (E) values for terms, which were then filtered as explained above.

To rank target genes, we created a GREAT ontology with each gene as its own term. Genes were ranked by the region-based binomial P-value, thus prioritizing genes with an unexpectedly high number of binding sites in the regulatory domain given the size of the assigned domain.

To unify human and mouse predictions, we first manually verified all mappings of motifs to human and mouse transcription factors. We then mapped orthologous genes and binding sites between species. Human and mouse orthologous target genes were defined as top BLASTP hits from the UCSC Table Browser hg18.mmBlastTab table, collapsing transcripts into loci through UCSC gene clusters (Kent et al. 2002). Binding site predictions were considered orthologous if they were identified as nearest matches in the multiple alignment in binding site prediction (see above).

Optimality of PRISM parameters

The PRISM method requires multiple parameter and threshold choices for binding site prediction and then inference of TF function. To optimize our approach, we evaluate multiple parameter and design choice combinations using the objective measure of the number of PRISM function predictions (derived from target gene annotations) confirmed by the ontologies (from an identical annotation for the regulating TF itself) (see Fig. 3D). We optimized parameter values using coordinate descent (in which one parameter is varied with all others fixed, iterating through the different parameters), starting from different initial parameter settings as seed. To test our design choices, we also varied the ways in which certain operations were performed, including an information content versus log likelihood interpretation of PWMs, passing a fixed number of binding sites to GREAT versus passing a variable number of sites meeting a uniform FDR threshold, defining the E-value for the functional enrichments as the fraction observed in any shuffles or as the fraction observed in shuffles that had a P-value at least as significant as the one observed in the real data set, the choice of top 20 terms per ontology before or after applying the E-value filter, changing the order in which our filters are applied and more. The approach and parameter settings we describe maximize the fraction of annotations with direct ontology support, from the large number of alternatives tested (data not shown). Note that this approach does not explicitly optimize the FDR of TF-term associations; thus, the TF function FDR provides an independent measure of the quality of the selected parameters.

Enhancer assays

Cell line/primary cell culture

The mPAC cell line was grown in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% Fetal Bovine Serum (FBS; Life Technologies). Normal Human Bronchial/Tracheal Epithelial Cells (NHBE; Lonza Walkersville, Inc.) were grown in Clonetics Bronchial/Tracheal Epithelial Growth Medium (BEGM). Normal Human Umbilical Vein Endothelial Cells (HUVEC; Lonza Walkersville, Inc.) were grown in Clonetics Endothelial Growth Medium (EGM; Lonza Walkersville, Inc.). Human Umbilical artery Smooth Muscle Cells (UaSMC; Lonza Walkersville, Inc.) were grown in Clonetics Smooth Muscle Growth Medium (SmGM; Lonza Walkersville, Inc.).
Plasmids
MYF6 (EMSV-MRF4 (puro), rat myf6) was a gift of Michael Rudnicki (Sabourin and Rudnicki 2000) (Addgene plasmid 14713). RUNX1 (pCMV5-AML1B [human runx1]) was a gift of Scott Hiebert (Meyers et al. 1995) (Addgene plasmid 12426). STAT1 (Stat1 alpha Flag prC/CMV [human stat1 alpha]) was a gift of Jim Darnell (Horvath et al. 1995) (Addgene plasmid 8691). MEF2A (pCGN-MEF2A [human mef2a]) was a gift of Ron Prywes (Han and Prywes 1995) (Addgene plasmid 32958).

Cloning
The firefly luciferase reporter vector pGL4.23 (Promega) was modified for ligation independent cloning (Du et al. 2011) by cloning the annealed oligos:

**LIC fwd site:** 5'- cGCTCCTCGGATGAGGGTATCCACCTTACCCGAAGAGCa-3'

**LIC rev site:** 5'- aqgctGCTCCTCGGATGAGGGTATCCACCTTACCCGAAGAGCggtac-3'

into the KpnI and HindIII sites of the pGL4.23 vector. The vector was prepped by digesting with EcoRv and NotI.BspQI (New England Biolabs). Human genomic DNA (Clonetech) was amplified using target-specific primers with the sequence ggtagggactc on the forward primer 5' end and ggtagggactc on the reverse primer 5' end. Primers were synthesized by Elim Biopharm. Inserts were treated with T4 DNA polymerase in the presence of 10 mM GTP, annealed to the treated vector, and transformed according to published methods (Du et al. 2011). The primers used for cloning are listed in Supplemental Table 14.

Transfections and luciferase assay
Cells were cultured to 80%–90% confluence and transfected using Lipofectomine LTX and PLUS reagent according to the manufacturer's instructions (Life Technologies). Transfections were done in a 96-well format using a 1-µL LTX:250 ng plasmid ratio. The plasmids transfected consisted of 200 ng of reporter construct and 50 ng of TF expression plasmid or control plasmid pCAG-Neo. Media was changed 4–6 h after transfection, and luciferase assays were done 24 h after transfection.

Data access
PRISM predictions for the human and mouse genomes are available at http://PRISM.stanford.edu. The PRISM portal offers an interface to explore our predictions from the perspective of transcription factors, biological roles, target genes, or target binding sites/regions (Supplemental Fig. 13). PRISM integrates with GREAT and the UCSC Genome Browser (Kent et al. 2002).

References
Allen HL, Flanagan SE, Shaw-Smith C, De Franco E, Akerman I, Caswell R, Ferrer J, Hattersley AT, Eilland S. 2011. GATA6 haploinsufficiency causes pancreatic agenesis in humans. Nat Genet 44: 20–22.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. 2000. Gene Ontology: Tool for the unification of biology. Nat Genet 25: 25–29.
Bejerano G, Pheasant M, Makunin I, Stephen S, Kent WJ, Mattick JS, Haussler D. 2004. Ultraconserved elements in the human genome. Science 304: 1321–1325.
Berger MF, Badis G, Gehrke AR, Talukder S, Philippakis AA, Penna-Castillo L, Alveyre TM, Minaimneh S, Botvinnik OB, Chan ET, et al. 2008. Variation in homeodomain DNA binding revealed by high-resolution analysis of sequence preferences. Cell 133: 1266–1276.
Blow MJ, McCulley DJ, Li Z, Zhang T, Akymya JA, Holt A, Plajzer-Frick I, Shoukry M, Wright C, Chen F, et al. 2010. ChIP-Seq identification of weakly conserved heart enhancers. Nature 489: 57–74.
Blake JA, Buil CT, Eppig JT, Kadim JA, Richardson JE. 2009. The Mouse Genome Database genotypes—phenotypes. Nucleic Acids Res 37: D712–D719.
Bryne JC, Valen E, Tang MH, Marstrand T, Winther O, da Piedade I, Krogh A, Lenhard B, Sandelin A. 2008. JASPAR, the open access database of transcription factor-binding profiles: New content and tools in the 2008 update. Nucleic Acids Res 36: D102–D106.
Caspi R, Foerster H, Fulcher CA, Kaipa P, Krümmemacher M, Latendresse M, Paley S, Rhee SY, Shearer AG, Tissier C, et al. 2008. The MetaCyc Database of metabolic pathways and enzymes and the BioCyc collection of pathway/Genome Databases. Nucleic Acids Res 36: D623–D631.
Cerami EG, Bader GD, Gross BE, Sander C. 2006. cPath: Open source software for collecting, storing, and querying biological pathways. BMC Bioinformatics 7: 497.
Cheng Y, King DC, Dore LC, Zhang X, Zhou Y, Zhang Y, Dornam C, Abebe D, Kumar SA, Chiaromonte F, et al. 2008. Transcriptional enhancement by GATA1-occupied DNA segments is strongly associated with evolutionary constraint on the binding site motif. Genome Res 18: 1996–2005.
Corbo JC, Lawrence KA, Karlstetter M, Myers CA, Abdalaziz M, Dirkes W, Welgelt K, Seifert M, Benes V, Fritsche LG, et al. 2010. CRX ChIP-seq reveals the cis-regulatory architecture of mouse photoreceptors. Genome Res 20: 1521–1535.
Das D, Nahle Z, Zhang MQ, 2006. Adaptively inferring human transcriptional subnetworks. Mol Syst Biol 2: 0006–0029.
Down TA, Bergman CM, Su J, Hubbard TJ. 2007. Large-scale discovery of promoter motifs in Drosophila melanogaster. PLoS Comput Biol 3: e7.
Du R, Li S, Zhang X. 2011. A modified plasmid vector pCMV-3Tag-LIC for rapid, reliable, ligation-independent cloning of polymerase chain reaction products. Anal Biochem 408: 557–559.
Fogelgren B, Yang S, Sharp IC, Huckstep OJ, Ma W, Sompopun SJ, Carlson EC, Uyehara CF, Lozanoff S. 2009. Deficiency in Six2 during prenatal development is associated with reduced nephron number, chronic renal failure, and hypertension in Br/+ adult mice. Am J Physiol Renal Physiol 296: F1166–F1178.
Genuario RR, Perry RP. 1996. The cA-binding protein can serve as both an activator and repressor of ribosomal protein gene transcription. J Biol Chem 271: 4388–4395.
Han TH, Prywes R. 1995. Regulatory role of ME2D in serum induction of the c-jun promoter. Mol Cell Biol 15: 2907–2915.
He A, Kong SW, Ma O, Pu WT. 2011. Co-occupancy by multiple cardiac transcription factors identifies transcriptional enhancers active in heart. Proc Natl Acad Sci USA 108: 5632–5637.
Hill CS, Wynn JE, Teismann R. 1995. The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRE. Cell 81: 1159–1170.
Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA. 2009. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci* **106**:9362–9367.

Horvitz CM, Wei D, Darnell JE Jr. 1995. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. *Genes Dev* **9**:984–994.

Jin S, Zhao H, Yi Y, Nakata T, Kalota A, Gewirtz AM. 2010. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. *J Clin Invest* **120**:593–606.

Jin W, Goldfine AB, Boes T, Henry RR, Ciaraldi TP, Kim EY, Emecan M, Fitzpatrick C, Sen A, Shah A, et al. 2011. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. *J Clin Invest* **121**:918–929.

Jolma A, Kivioja T, Toivonen J, Cheng L, Wei G, Enge M, Taipale M, Vaquerizas JM, Yan J, Silliman MJ, et al. 2010. Multiplexed massively parallel SELEX for characterization of human transcription factor binding specificities. *Genome Res* **20**:861–873.

Joung JK, Sander JD. 2012. TALENS: A widely applicable technology for targeted genome editing. *Nat Rev Mol Cell Biol* **14**:49–55.

Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, Daigo Y, Nakamura Y, Miyoshi Y, Murase K, Saito M, Imamura M, Oh K. 2010. Mechanisms of functional genomics. *Cell Stem Cell* **11**:633–648.

Kerst B, Mennerich D, Schuelke M, Stoltenburg-Didinger G, von Moers A, Podlasek CA, Clemens JQ, Bushman W. 1999. AML-1B-dependent transcriptional activation. *Mol Cell Biol* **19**:747–783.

Kohler G, Mombaerts P. 1996. Generation of mice lacking the myeloid transcription factor c-Myb. *Nature* **380**:841–845.

Kollar K, Rinaldi NJ, West M, Botstein D, Brown PO. 2002. Parallel SELEX for characterization of human transcription factor binding specificities. *Genome Res* **12**:996–1006.

Koiti B, Nishimura S, Imai K, Hamada Y, Ishida Y, Tsuchihashi M, Oishi K, Nakamura Y, Hirata H, Matsumoto M, Furukawa T, Li H, Zhao H, Itoh H, Xue HH. 2010. Critical requirement of GABP alpha beta heterodimer in acute myeloid leukemia. *Proc Natl Acad Sci* **107**:21501–21506.

Kumar A, Chakravarti A, West QC, Subramaniam S, Reinert K, Scherf U. 2004. Relaxed Procrustes analysis for the comparison of mouse and human gene expression patterns. *Genome Res* **14**:730–737.

Kusama T, Takahashi T, Inoue S, Doi K, Nakahara H, Honda K, Sato H, Kinoshita T. 2007. Binding specificities of parallel SELEX for characterization of human transcription factor binding specificities. *Genome Res* **20**:861–873.

Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, Rubin EM, et al. 2001. Initial sequencing and analysis of the human genome. *Nature* **409**:860–921.

Lee CH, Sun Y, Yoo J, Shen T, Sethuraman G, Cui Y, Lee S, Lee J, West J, et al. 2010. The UCSC Genome Browser database. *Nucleic Acids Res* **38**:D754–D763.

Lee J, Lee YH, Hwang HY, Bae SS, Hwang SW, Kim TH, Yang JG, Kim JS, Ham SY, et al. 2009. Novel mouse models generated by CRISPR/Cas9-mediated genome editing. *Nat Biotechnol* **27**:631–633.

Lee WW, Zhang L, Biber K, Liu J, Chen YT, Lee EY, Wang X, Lin S, Wang X, et al. 2011. Targeted genome editing. *Science* **332**:1230–1233.

Lee Y, Shin J, Kwon Y, Yoon SI, Lee H, Kang DW, Lee JS, Byun HS, Cho JH, et al. 2010. Genome-wide association loci for human diseases and traits. *Science* **329**:1036–1040.

Lee Y, Shin J, Kwon Y, Yoon SI, Lee H, Kang DW, Lee JS, Byun HS, Cho JH, et al. 2010. Genome-wide association loci for human diseases and traits. *Science* **329**:1036–1040.

Lee Y, Shin J, Kwon Y, Yoon SI, Lee H, Kang DW, Lee JS, Byun HS, Cho JH, et al. 2010. Genome-wide association loci for human diseases and traits. *Science* **329**:1036–1040.

Lee Y, Shin J, Kwon Y, Yoon SI, Lee H, Kang DW, Lee JS, Byun HS, Cho JH, et al. 2010. Genome-wide association loci for human diseases and traits. *Science* **329**:1036–1040.

Levchenko A, Gilbert DM, Schachner M, Reynolds AM, Segal E, Widom J. 2007. Dynamic regulation of the p53 network. *Science* **316**:545–548.

Levchenko A, Gilbert DM, Schachner M, Reynolds AM, Segal E, Widom J. 2007. Dynamic regulation of the p53 network. *Science* **316**:545–548.

Ley K, Pils B, Pohl T, Zhang Y, Wang J, Brandt DE, Vogelstein B, Kinzler KW. 2008. The direct role of c-Myc in G1 cell cycle progression. *Nature* **451**:520–526.

Li H, Li J, Mai F, Chen Z, Cai X, Zhang X, Xu Z, Zhan Y, Zhang Y. 2011. Single-nucleotide polymorphisms of HLA genes and susceptibility to breast cancer in the Japanese population. *Jpn J Cancer Res* **102**:292–297.

Lyon MF, Sturgeon MK, Emerson CP Jr. 2002. Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. *Annu Rev Cell Dev Biol* **18**:747–783.

Lyon MF, Sturgeon MK, Emerson CP Jr. 2002. Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. *Annu Rev Cell Dev Biol* **18**:747–783.

Lyon MF, Sturgeon MK, Emerson CP Jr. 2002. Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. *Annu Rev Cell Dev Biol* **18**:747–783.

Lyon MF, Sturgeon MK, Emerson CP Jr. 2002. Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. *Annu Rev Cell Dev Biol* **18**:747–783.

Lyon MF, Sturgeon MK, Emerson CP Jr. 2002. Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. *Annu Rev Cell Dev Biol* **18**:747–783.

Lyon MF, Sturgeon MK, Emerson CP Jr. 2002. Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. *Annu Rev Cell Dev Biol* **18**:747–783.

Lyon MF, Sturgeon MK, Emerson CP Jr. 2002. Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. *Annu Rev Cell Dev Biol* **18**:747–783.

Lyon MF, Sturgeon MK, Emerson CP Jr. 2002. Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. *Annu Rev Cell Dev Biol* **18**:747–783.

Lyon MF, Sturgeon MK, Emerson CP Jr. 2002. Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. *Annu Rev Cell Dev Biol* **18**:747–783.

Lyon MF, Sturgeon MK, Emerson CP Jr. 2002. Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. *Annu Rev Cell Dev Biol* **18**:747–783.